Traders Sell Johnson & Johnson (JNJ) on Strength (JNJ)

Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Monday. $180.60 million flowed into the stock on the tick-up and $255.41 million flowed out of the stock on the tick-down, for a money net flow of $74.81 million out of the stock. Of all companies tracked, Johnson & Johnson had the 22nd highest net out-flow for the day. Johnson & Johnson traded up $1.92 for the day and closed at $133.15

JNJ has been the topic of several recent research reports. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Finally, JPMorgan Chase & Co. cut shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $146.16.

The stock has a market capitalization of $357,710.00, a price-to-earnings ratio of 341.41, a price-to-earnings-growth ratio of 2.23 and a beta of 0.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. The business had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same period last year, the business earned $1.58 EPS. The company’s revenue was up 11.5% compared to the same quarter last year. sell-side analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 861.54%.

Several large investors have recently added to or reduced their stakes in the company. Goodman Financial Corp purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $104,000. Harding Loevner LP purchased a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $106,000. Stelac Advisory Services LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $108,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Finally, IHT Wealth Management LLC raised its position in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the last quarter. Institutional investors and hedge funds own 65.58% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Traders Sell Johnson & Johnson (JNJ) on Strength (JNJ)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/19/traders-sell-johnson-johnson-jnj-on-strength-jnj-2.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply